Zoetis Enhances Diagnostics Portfolio with VitalRADS Acquisition and Vetscan Opticell™ Expansion

Zoetis Inc (NYSE: ZTS) has taken significant strides this week to deepen its diagnostic services portfolio, signaling a strategic expansion that augments its competitive edge in the animal health market. These developments come amid ongoing shifts in demand across its companion animal business.

Completed VitalRADS Acquisition Expands Imaging Services

In July, Zoetis finalized the acquisition of VitalRADS, a veterinary teleradiology services platform, completing a transaction that had been previously announced. This integration brings around-the-clock access to board-certified veterinary specialists via a cloud-based teleradiology system, extending Zoetis’ diagnostic capabilities beyond traditional in-vitro testing.

The move supports the company’s broader vision of building an end-to-end Virtual Reference Lab, enabling veterinarians with enhanced imaging interpretation and workflow support.

Vetscan Opticell™ Gains Advanced Hematology Capability

Also this week, Zoetis expanded the functionality of its Vetscan Opticell™ point-of-care hematology analyzer to include cellular hemoglobin concentration mean—a capability formerly only offered by reference laboratories. This upgrade delivers deeper diagnostic insights directly at the clinic level, improving efficiency and supporting more accurate clinical decision-making.

Strategic Significance for Diagnostics and Investor Perspective

These enhancements reinforce Zoetis’ positioning within the animal health sector by bringing greater scale and depth to its diagnostics and telemedicine offerings. Integrating VitalRADS adds teleradiology to its portfolio while the Opticell™ upgrade boosts point-of-care utility—both pivotal in addressing evolving veterinarian and pet-owner needs.

Zoetis’ stock (ticker ZTS) recently traded at $75.65 as of October 12, 2026, reflecting a 0.87% change. While market movement may not be directly attributable to these diagnostics developments absent confirmed reporting, they mark tangible progress in the company’s broader growth strategy.

Looking Ahead

As Zoetis continues to target integrated diagnostic solutions, investors and stakeholders may monitor the rollout and adoption of these services in veterinary clinics. The success of the VitalRADS platform and enhanced Opticell™ utility will offer insight into whether these investments can catalyze broader revenue growth and reinforce Zoetis’ differentiation in a rapidly evolving animal health ecosystem.